CoChat

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

Open access
Harousseau, Jean-Luc, Palumbo, Antonio, Richardson, Paul G., Schlag, Rudolf, Dimopoulos, Meletios A., Shpilberg, Ofer, Kropff, Martin, Kentos, Alain, Cavo, Michele, Golenkov, Anatoly, Komarnicki, Mieczyslaw, Mateos, Maria-Victoria, Esseltine, Dixie-Lee, Cakana, Andrew, Liu, Kevin, Deraedt, William, van de Velde, Helgi, San Miguel, Jesús F. · 2010 · Blood
Cited by 105

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

The phase 3 Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone study in newly diagnosed multiple myeloma patients ineligible for high-dose therapy demonstrated that bortezomib-melphalan-prednisone (VMP) was superior to melphalan-prednisone across all efficacy end points. We assessed the prognostic impact of response on time-to-event parameters in the intent-to-treat population. Patients received nine 6-week cycles of treatment. Time to progression, time to next therapy, and treatment-free interval were associated with quality of response. When European Group for Blood and Marrow Transplantation criteria were used, complete response (CR) was associated with significantly longer time to progression (hazard ratio [HR] = 0.45, P = .004), time to next therapy (HR = 0.46, P = .0004), and treatment-free interval (HR = 0.38, P < .0001) versus partial response, but there was no significant difference in overall survival (HR = 0.87, P = .54); similar differences were seen with CR versus very good partial response by uniform criteria. Quality of response improved with prolonged VMP treatment, with 28% of CRs achieved during cycles 5-9. CR duration appeared similar among patients with “early” (cycles 1-4) and “late” CRs (cycles 5-9) and among patients receiving 9 versus < 9 cycles of bortezomib within VMP. These results highlight that CR is an important treatment goal and support prolonged VMP therapy to achieve maximal response. This study is registered at http://www.clinicaltrials.gov as NCT00111319.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-03-275800

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 105

Metadata

Authors
Harousseau, J.-L., Palumbo, A., Richardson, P. G., Schlag, R., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Kentos, A., Cavo, M., Golenkov, A., Komarnicki, M., Mateos, M.-V., Esseltine, D.-L., Cakana, A., Liu, K., Deraedt, W., van de Velde, H., & San Miguel, J. F.
Venue
Blood
Published
2010-11-11
Volume
116
Issue
19
Pages
3743-3750
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2062373072
Cited by
105
References
8
FWCI
7.90
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. https://app.cochat.ai/papers/10.1182/blood-2010-03-275800
The paper
Harousseau, J.-L., Palumbo, A., Richardson, P. G., Schlag, R., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Kentos, A., Cavo, M., Golenkov, A., Komarnicki, M., Mateos, M.-V., Esseltine, D.-L., Cakana, A., Liu, K., Deraedt, W., van de Velde, H., & San Miguel, J. F. (2010). Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood. https://doi.org/10.1182/blood-2010-03-275800

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.